Why India's Pharma and Biopharma Sector Is Entering a New Phase

Executive Summary

For decades, India has been recognized as one of the world's leading producers of generic medicines, earning its reputation as the pharmacy of the world. Today, however, the industry is entering a new phase of development. Driven by advances in biologics, growing contract manufacturing opportunities, increased investment in research ecosystems, and the emergence of advanced therapeutics, India's pharmaceutical sector is gradually evolving from a volume-driven generic model toward a more innovation-oriented and technology-intensive future.

Generics: Still the Foundation

India's generic pharmaceutical industry remains one of the largest and most important in the world. Indian manufacturers supply a significant share of global generic drug volumes — including to regulated markets in the US, EU, and UK. This foundation of scale, regulatory compliance capability, and cost efficiency is not being abandoned; it is being built upon.

The Biologics and Biosimilars Shift

Biologics — including monoclonal antibodies, recombinant proteins, and vaccines — represent the fastest-growing segment of the global pharmaceutical market. India is investing in biologic manufacturing capacity, biosimilar development, and the cold-chain infrastructure needed to support it. Several Indian companies have successfully launched biosimilars in regulated markets, establishing proof of concept for the sector's ability to compete in higher-complexity therapeutics.

Contract Development and Manufacturing (CDMO)

Global pharmaceutical companies are increasingly outsourcing formulation development, active pharmaceutical ingredient (API) manufacturing, and clinical supply to trusted CDMO partners. India is well-positioned to capture a growing share of this outsourcing — combining established regulatory track records, large API manufacturing capacity, and competitive cost structures.

Research and Innovation Ecosystem

India's pharmaceutical research ecosystem is expanding. Academic-industry partnerships, government research grants, dedicated pharma innovation parks, and growing venture funding for biotech startups are creating a more dynamic innovation environment. The country is increasingly active in drug discovery, diagnostics, and medical device development — not just manufacturing.

What This Means for Businesses and Investors

India's pharmaceutical and biopharma sector presents a layered investment opportunity. The established generics platform provides stable cash flows and scale. The evolving biologics and CDMO sectors offer higher-growth opportunities with more complex barriers to entry. For global pharma companies, India is a manufacturing partner, a research collaborator, and a growing end-market.